CYTOKINETICS INC

Cytokinetics is a biopharmaceutical company dedicated to discovering, developing, and commercializing small-molecule therapeutics targeting muscle biology to treat severe cardiovascular and neuromuscular diseases. Its core research centers on the cytoskeleton and sarcomere mechanics, organized into cardiac and skeletal muscle contractility programs. The company's first commercial product is MYQORZO (aficamten), an oral cardiac myosin inhibitor approved for adults with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics also advances a pipeline of clinical candidates, including omecamtiv mecarbil, ulacamten, and CK-089. Its commercial focus directs therapies toward specialized customer segments, primarily cardiologists, academic centers of excellence, and focused healthcare providers.

The company maintains commercial sales and distribution operations in the United States and collaborates with licensing partners, including Sanofi in China and Bayer in Japan, to reach patient populations across North America, Europe, and Asia. Regulatory approvals for MYQORZO cover the United States, the European Union, and China, with planned commercial rollouts extending into Germany and additional major European nations. The text does not disclose the location of the corporate headquarters.

Summary of the business section of Cytokinetics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 673 employees.”